Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer

US9422234B2 · kind B2 · utility

Assignee

• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• Sachin Chandran · Highland Park, US
• Sangeeta Ray · Ellicott City, US
• Martin G. Pomper · Baltimore, US
• Samuel R. Denmeade · Ellicott City, US
• Ronnie C. Mease · Fairfax, US

Key dates

• Filing date: Nov 26, 2008
• Grant date: Aug 23, 2016
• Expiry date: Sep 21, 2030

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S977/911
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.